Cell Therapy Market Research Report- Global Forecast till 2030

Cell Therapy Market Research Report Information By Cell Type (Stem Cell, {Bone Marrow, Blood, Umbilical Cord-Derived, Adipose-Derived Stem Cell, and others [Placenta, and Nonspecific cells]}, and Non-stem Cell), By Therapy Type (Autologous, and Allogeneic), By Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and others), By End-User (Hospitals & Clinics, and Academic & Research Institutes), and By Region (North America, Europe, Asia-Pacific, and the Rest of the World)—Forecast till 2030

ID: MRFR/LS/3630-CR | February 2021 | Region: Global | 95 Pages         

Cell Therapy Market Speak to Analyst Request a Free Sample

Cell Therapy Market

Cell Therapy Market is anticipated to reach USD 26.9 Billion by 2030 at CAGR of 9.3% over the forecast period 2022-2030

By Type Autologous & Allogeneic
By Product Consumables Equipment & Software & Other Services
By Technique Stem Cell Therapy Cell Vaccine Adoptive Cell Transfer (ACT) Fibroblast Cell Therapy Chondrocyte Cell Therapy
By Technology Viral Vector Technology Cell Immortalization Technology Genome Editing Technology
By End User Hospitals & Clinics & Others
Key Players
Companies Profiled   Mesoblast Ltd    Vericel Corporation    Osiris Therapeutics    Inc.    JCR Pharmaceuticals Co.    Ltd.    NuVasive    Pharmicell Co.    RTI Surgical Holdings    AlloSource    Holostem Terapie Avanzate S.R.L.    Medipost Co.
Market Driving Forces   Technological Advancements in Vegetable Seeds to Favor Market   Increase in Seed Production Capacity by Private Companies to Remain Effective Growth Booster   High Demand for Organic Seeds to Boost cell therapy market Revenue
Request a Free Sample

Global Cell Therapy Market Research (MRFR Insights)

The cell therapy market size is projected to reach USD 26.9 Billion by 2030, at a CAGR of 9.3% from 2022 to 2030. Cell therapy contains transplanting cells into the patient's body to heal diseases. These cells may arise from the patient's body and are known as autologous cells or from the different donors, known as allogeneic cells. Pluripotent-type cells can be converted into any cell type in the body, whereas multipotent cells can convert into other cell types. Still, their repertoire is more restricted than that of pluripotent cells. Primary cells are of a fixed type. The type of cells administered relies on the treatment type. Stem cells utilized for replacement are either stem cells or emanate from stem cells. The market forecast for cell therapy is anticipated to increase owing to the advancement in clinical studies about the development of cellular therapies, the growing adoption of cell regeneration therapy, and the introduction of novel platforms and technologies. The therapy that combats malignant cells by re-developing the WBCs is understood as CAR T cell therapy. CAR T-cell therapy is a mixture of cell therapy and gene therapy.

COVID-19 Impact Analysis

The impact of the COVID-19 pandemic on the market growth of the cell therapy is positive. Cell therapies got momentum in the market owing to the pandemic. For instance, in April 2020, Calidi Biotherapeutics Inc. reported that the FDA had approved the Investigational New Drug application approved by its partner, Personalized Stem Cells, Inc., for diagnosing and treating COVID-19 patients using stem cell therapy. Thus, this had a positive effect on the market growth of cell therapy.

 Cell Therapy Market Dynamics

The market trends of Cell therapy include the growing incidents of chronic disorders and infections. In addition, the rising cases of diabetes and increasing adoption of regenerative medicine are also fueling cell therapy market size. According to the International Diabetes Federation Diabetes Altas, approximately 573 million people had diabetes in 2021 ly, which is expected to rise by 643 million by 2030. Moreover, the increasing number of research studies and clinical trials are also boosting the market growth of the cell therapy.

Market Drivers

  • Growing approvals for cell-based therapies

Cell therapies are getting approved efficiently by government agencies. Since FDA-approved products are readily obtainable in developing countries, these are anticipated to drive the growth of the stem market over the forecast period. For instance, in September 2020, FDA granted Investigational New Drug approval to Stemedica Cell Technologies, Inc. for conducting phase II trials for intravenously administered allogeneic MSCs in covid-19 patients. Ischemic-tolerant MSCs have various properties that make them attractive novel biological therapy for COVID-19, such as their immunomodulatory effects, low immunogenicity, and capacity for suppressing excessive pro-inflammatory responses.

  • Increasing research and development activities

  • Increase in the demand for stem cell therapy for knees

Market Restraints:

  • High capital investments for cell therapy plants

People seeking the most up-to-date alternative remedies for several ailments have become increasingly interested in stem cell therapy. Every day, new treatments are established, and individuals all over the globe are shifting to them rather than standard drug regimens and hospital visits. Despite the increasing demand for stem cell therapies, they are still incredibly costly to develop. Moreover, the high expense of cell therapies is a significant challenge to expanding the market.

  • Lack of skilled and trained workforce.

Market Opportunities:

  • Growing government initiatives

The government is increasingly investing in research and development activities. In November 2019, the Australian government issued the stem cell therapies mission, the journey of 10 years for stem cell research. The Medical Research Future Fund would receive USD 102 million to support stem cell research to create novel medicines. Thus, the increasing government initiatives are creating lucrative opportunities for the growth of the market.

  • Increase in the number of regulations to promote stem cell therapy

Cell Therapy Market Segmentation

Cell Type Insights

The market segmentation of cell therapy, based on cell type, is stem cells, {bone marrow, blood, umbilical cord-derived, adipose-derived stem cell, and others [placenta, and nonspecific cells]}, and non-stem cells. The stem cell therapy category held a prominent share in 2021 because of increased demand for innovative and better medicines to treat autoimmune, neurological, and cardiovascular disorders. Stem cell therapy is also known as cell regeneration therapy. However, non-stem cell is the fastest-growing category during the forecast period. Non-stem cell therapy can enhance the growth of new healthy skin tissue and collagen production.

Therapy Type Insights

The market segments of cell therapy, based on the therapy type, is autologous and allogeneic. The autologous category had a significant share in 2021 due to several advantages associated with autologous transplants, such as easy availability, no need to identify an HLA-matched donor, lower risk of life-threatening complications, no risk of GVHD, and no necessity of immunosuppressive therapy. However, the allogeneic category is the fastest-growing owing to the high cost associated with allogenic transplants and relatively lower relapse rates.

Therapeutic Area Insights

The cell therapy market research, based on therapeutic area, is malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. The malignancies category had a significant share in 2021 due to an increase in the adoption of cell therapy for treating malignancies. Besides this, musculoskeletal disorders are the fastest-growing category as a result of increased prevalence of chronic diseases such as arteries.

End-User Insights

The cell therapy market report, based on end-user, is hospitals & clinics and academic & research institutes. In 2021, the hospitals & clinics category held a prominent market share due to increased demand for gene and cell therapy during the forecast period. However, academic & research institutes are the fastest-growing category. The stem cells are mainly being utilized for research projects, which has led to a considerable revenue share for the research use.

Global Cell Therapy Market Share by Region, 2021 (%)
Cell Therapy Market Share by Region, 2021
Cell Therapy Market Overview, by Region

By region, the market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the most extensive market share. Asia-Pacific is projected to exhibit the highest CAGR during the review period.

North America

North America dominated the market in 2021 due to growing incidences of chronic disorders and increasing investments in developing the market. In the US, Cellino Biotech, an independent cell treatment manufacturing firm, secured a first investment round of USD 80 million in January 2022. Cellino likes to make stem cell-based medicines more attainable to build the first self-contained human cell foundry by 2025. In addition, the market in the North American region is also being driven by increasing applications of stem cell technologies for the treatment of different diseases. Moreover, the increasing research and development activities are encouraging the growth of the North American market.


Asia-Pacific is expected to develop at the fastest growth rate during the forecast period. China dominates the market in the Asia-Pacific region. The favorable government regulations contribute to the growth of the market in this region. Asia-Pacific has a significant potential for market growth, as it accounted for approximately 4.6 billion of the human population in 2019, which might act as a forthcoming patient base. Furthermore, emerging countries such as China and India are expected to grow due to enhanced healthcare facilities, low prices, and expanded knowledge of cell therapy.

Cell Therapy Market Competitive Landscape

The market includes tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach with diverse product portfolios. Companies such as Mesoblast Ltd, Vericel Corporation, Osiris Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., NuVasive, Inc., Pharmicell Co., Ltd., RTI Surgical Holdings, Inc., AlloSource, Holostem Terapie Avanzate S.R.L., and Medipost Co., Ltd. dominate the market because of product differentiation, financial stability, strategic developments, and diversified regional presence. The players are concentrating on supporting research and development. Furthermore, they embrace strategic growth initiatives, such as development, product introduction, joint ventures, and partnerships, to strengthen their market position and capture an extensive customer base. For instance, in February 2022, Thermo Fisher Scientific established new integrated commercial packaging and distribution services developed to transform therapies from clinic to commercial launch for patients across Europe and the US. The latest Patheon Commercial Packaging Services is an end-to-end solution blending distribution, GMP storage, ultracold & cryogenic packaging, and serialization that developers need to support their logistics strategies.

Prominent players in the market include Kolon TissueGene Inc., AlloSource, Holostem Terapie Avanzate S.R.L., AlloSource, Holostem Terapie Avanzate S.R.L., Castle Creek Biosciences Inc., Anterogen Co. Ltd, Celgene Corporation, and Tameika Cell Technologies Inc. among others.

Scope of the Cell Therapy Market Report

Cell Type Outlook

  • Stem Cell

    • Bone Marrow

    • Blood

    • Umbilical Cord-Derived

    • Adipose-Derived Stem Cell

    • Others (placenta and nonspecific cells)

  • Non-stem Cell

Therapy Type Outlook

  • Autologous

  • Allogeneic

Therapeutic Area Outlook

  • Malignancies

  • Musculoskeletal Disorders

  • Autoimmune Disorders

  • Dermatology

  • Others

End-User Outlook

  • Hospitals & Clinics

  • Academic & Research Institutes

Region Outlook

  • North America

    • US

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia and New Zealand

    • Rest of Asia-Pacific

  • Rest of the World

    • South America

    • Middle East

    • Africa

Objectives of the Study

The objectives of the study are summarized in 5 stages. They are as mentioned below:

Cell Therapy Market Forecast & Size:

To identify and estimate the market size for the market segmented by cell type, Therapy Type, Therapeutic Area, and end-user by value (in US dollars). Also, to understand the consumption/demand created by consumers of cell therapy between 2022 and 2030

Market Landscape and Trends:

To identify and infer the drivers, restraints, opportunities, and challenges for the market

Market Influencing Factors:

To find out the factors which are affecting the sales of cell therapy among consumers

Impact of COVID-19:

To identify and understand the various factors involved in the market affected by the pandemic

Company Profiling:

To provide a detailed market analysis of the major companies operating in the market. The profiling will include the financial health of the company in the past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.

Intended Audience

  • Hospitals & Clinics

  • Academic & Research Institutes

  • Governments, Associations, and Industrial Bodies

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 26.9 Billion
  CAGR   9.3%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Technology, Application, Delivery Mode, Component, and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
  Key Vendors   Kolon TissueGene Inc., AlloSource, Holostem Terapie Avanzate S.R.L., AlloSource, Holostem Terapie Avanzate S.R.L., Castle Creek Biosciences Inc.,
  Key Market Opportunities   Increase in the number of regulations to promote stem cell therapy
  Key Market Drivers   Increasing adoption of regenerative medicine, and the introduction of novel platforms and technologies

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The study period of the market is 2022 - 2030

The market is growing at a CAGR of 9.3% over the next 8 years.

Asia-Pacific is expected to register the highest CAGR during 2022 - 2030

North America held the largest share in 2021

Kolon TissueGene Inc., AlloSource, Holostem Terapie Avanzate S.R.L., AlloSource, Holostem Terapie Avanzate S.R.L., and Castle Creek Biosciences Inc. are the major companies operating in the market.